CD4 and neoplasm: Samples of pancreatic tissue and blood aliquots examined by flow cytometry for signs of an adaptive anti-tumor immune response (Figure 5a,b) revealed the percentage of CD4+ and CD8+ among CD3+ lymphocytes to be unchanged on day 14, i.e., following the conclusion of oncolytic construct administration.